Selentus Science is pleased to announce that its patent for TenaTac®, an innovative, adhesive surgical haemostat, has been allowed for grant in the UK, following an earlier grant in the USA. TenaTac is a Class III CE marked medical device that was approved for human surgical use in late 2019. TenaTac is now also available to veterinary surgeons in the UK; for further information please visit www.Selentus.com

This article was written by Medilink EM Member, Selentus Science.

For more information on Medilink Membership, click here

Latest Opportunities

Funding competition for digital therapeutics for mental health

UK registered businesses can apply for a share of up to £3.7m for R&D projects…

AI Airlock pilot call for applications

Funding competition information Following the launch webinar on 23 July 2024, candidates can now apply…

Explore the Chinese Market with EFEC

Lily Lin, CEO of Excellence First Enterprise Consultancy (EFEC), will be visiting China from 13…

Latest News

V Formation expands digital marketing capabilities with new hire

Nottingham-based marketing and PR agency, V Formation, has bolstered its digital marketing offering with the…

Interactive Software shares guide to data migration

Your data is one of your most valuable assets. Poor data quality can lead to…

Med-Di-Dia launches new Fractional Regulatory Service

The new service from Med-Di-Dia enables its specialists to act as ad-hoc support for various…